IP Cases — 2026
559 decisions across all jurisdictions
Page 6 of 19 · 559 total
Merck Sharp & Dohme LLC v.Halozyme, Inc. et al.
Merck Sharp & Dohme LLC has filed an IPR petition challenging Halozyme’s U.S. Patent 11,041,149 covering engineered PH20 hyaluronidase proteins. The petition alleges lack of written description, enablement, and anticipates all claims under prior art US‑275.
Merck Sharp & Dohme LLC v.Halozyme, Inc. et al.
Merck has filed an IPR petition challenging Halozyme’s ’656 patent covering engineered PH20 hyaluronidase proteins. The petition asserts lack of written description and enablement and that US‑275 anticipates all claims.
Amazon.com Services LLC et al. v.Smart Speaker LLC
Amazon has filed an IPR petition challenging 27 claims of Smart Speaker’s ’720 patent, asserting obviousness over a suite of prior‑art references covering microphones, WLAN, speakers, and lighting. The petition highlights a deficient examiner search and seeks cancellation of all challenged claims.
Novartis Ag v.Bdr Pharmaceuticals International Private Limited
This order addresses several interlocutory applications filed by Novartis Ag against Bdr Pharmaceuticals International. The court granted exemptions from pre-institution mediation and allowed additional documents, while also considering arguments regarding the scope of the defendants' license under the Patents Act.
Wirtgen Gmbh v.Controller General Of Patents, Designs and Trademarks and Ors
Wirtgen Gmbh appealed a rejection order issued by the Controller General of Patents, Designs and Trademarks. The rejection was based on lack of inventive step and insufficient claim definition under the Patents Act. The High Court found that the impugned order suffered from analytical and procedural deficiencies.
Daewoong Pharmaceutical Co. Ltd. v.Controller General Of Patents Designs and Trademarks
Daewoong Pharmaceutical appealed the rejection of its patent application (No. 201817048074) by the Controller General, which was based on non-patentability under Section 3(d). The appeal challenged the decision to reject the application despite submissions regarding improved therapeutic efficacy and stability data.
Sanofi - Aventis v.Controller General Of Patents, Designs and Trademarks And Anr.
Sanofi - Aventis appealed an order from the Assistant Controller of Patents & Designs. The appellant argued that the impugned order was perverse because it failed to adequately address arguments concerning lack of inventive steps and should have been based on Section 3(d) of the Patents Act, 1970.
HyGear B.V. v.Topsoe A/S (Language of Proceedings Order)
HyGear B.V., a defendant in main proceedings concerning EP3802413 (hydrogen production by steam methane reforming), requested the Local Division Düsseldorf to change the language of proceedings from German to English. The President of the Court of First Instance granted the application, finding that the balancing of interests favored HyGear, particularly given the accelerated nature of the proceedings and the need for efficient communication among defendants without reliance on translations.
Accord BioPharma, Inc. et al. v.Janssen Biotech, Inc. et al.
Accord BioPharma petitions the PTAB to invalidate claims 1‑7 of Janssen’s anti‑TNF antibody patent, asserting anticipation and obviousness based on Janssen’s own clinical‑trial data and FDA‑approved labeling.
Accord BioPharma, Inc. et al. v.Janssen Biotech, Inc. et al.
Accord BioPharma petitions to invalidate claims 1‑10 of US 982, alleging they are anticipated and obvious in view of a Janssen‑sponsored clinical trial and FDA‑approved labeling. The petition seeks institution of an IPR and cancellation of the claims.
Accord BioPharma, Inc. et al. v.Janssen Biotech, Inc. et al.
Accord BioPharma has filed an IPR petition seeking to invalidate claims 1‑7 of Janssen’s US 12,122,824 patent covering an IV golimumab regimen for psoriatic arthritis, arguing lack of novelty and obviousness based on a Janssen‑sponsored clinical trial and FDA‑approved labeling.
Accord BioPharma, Inc. et al. v.Janssen Biotech, Inc. et al.
Accord BioPharma petitions the PTAB to invalidate Janssen’s golimumab patent (US 11,041,020) on the basis that the claims are anticipated and obvious over the company’s own clinical‑trial protocol and other prior art.
Tv Today Network Limited v.News Laundry Media Private Limited
Tv Today Network Limited (Plaintiff) filed a suit alleging defamation, disparagement, and copyright infringement against News Laundry Media Private Limited (Defendant). The dispute centered on derogatory content aired by the Defendant. The court found that commercial disparagement was made out and granted an interim order directing the removal of specific defamatory remarks.
ITC Limited v.Philip Morris Products S.A.
ITC Limited appealed against an order that dismissed its post-grant opposition to Indian Patent No. 319780. The appeal challenged the dismissal on grounds that the impugned order was non-speaking and failed to consider crucial reply evidence and documents filed by ITC under Rule 59 of the Patents Rules, 2003. The Court found that the Controller had ignored categorical directions regarding these submissions.
Mati Therapeutics Inc v.Controller Of Patents And Designs
Mati Therapeutics Inc filed an appeal against the Controller of Patents and Designs. The court order addressed arguments regarding the possibility of amending patent claims to comply with Section 59 of the Patents Act, 1970, and whether such amendments could be reviewed at a de novo stage.
Dolby International AB v.Beko Germany GmbH a.o.
This case before the Local Chamber Düsseldorf of the Unified Patent Court concerned an infringement action and a counterclaim for revocation regarding European Patent EP 3 605 534, which relates to audio/video codecs used in smart TVs. The court addressed the FRAND defense raised by the defendants, examining whether Dolby held a dominant position under Article 102 TFEU and whether the defendants complied with the Huawei v. ZTE negotiation program. The court found in favor of Dolby on the infringement claim (granting injunction, information, and damages) and dismissed the defendants' revocation counterclaim.
EOFlow Co., Ltd. v.Insulet Corporation
The Court of Appeal dismissed EOFlow's appeal against the Milan Central Division's denial of its requests under R. 262.2 RoP to classify certain business information as confidential. The court held that trade secrets or confidential information lose their protected character when disclosed to the opposing party without a R. 262A RoP order or other restriction, and that a R. 262.2 RoP request does not automatically prevent the other party from disclosing the information.
GC Aesthetics Parentco Limited & Others v.Establishment Labs S.A.
This procedural order concerns a request by the defendants (a group of GC Aesthetics entities and Romed N.V.) for security for costs under Rule 158 RoP against the claimant Establishment Labs S.A. (LABS) in infringement proceedings concerning EP 3 107 487 B1. The defendants argued that LABS, incorporated in Costa Rica, posed an enforcement risk because Costa Rica had not ratified the Hague Judgement Convention and there was no precedent for enforcing UPC costs orders there. The Court ordered LABS to provide security of €600,000 within 21 days, either by deposit into a UPC account or by bank guarantee from an EU-licensed bank.
CUP&CINO Kaffeesystem-Vertrieb GmbH & Co. KG v.ALPINA Coffee Systems GmbH
The Local Chamber Düsseldorf of the Unified Patent Court found that ALPINA Coffee Systems GmbH infringed claim 2 of European Patent EP 3 398 487 B1 (owned by CUP&CINO) through its ALPINA Latte Perfetto Duo milk frother. The court dismissed ALPINA's counterclaim for revocation of the patent and granted relief including an injunction, destruction orders, information obligations, and recall orders, while holding that advertising materials are exempt from destruction under Art. 64(2)(e) UPCA.
Veolia Propreté, Valinea Energie, Maguin SAS v.Tiru
This case before the Central Division of the Unified Patent Court (Paris seat) concerned revocation actions against European patent EP 3 178 578 B1 owned by Tiru, relating to a waste incineration installation and associated process. The claimants (Veolia Propreté, Valinea Energie, and Maguin SAS) sought revocation of the patent on grounds including Article 123(3) EPC (extension of protection), prior public use, and lack of inventive step. The court rejected the revocation requests and maintained the patent in modified form according to Tiru's subsidiary request 2.0 (rectified version), with costs split 60% to the claimants and 40% to Tiru.
Krisp Technologies, Inc. v.Sanas.AI, Inc.
Krisp Technologies has filed a post‑grant review petition seeking to invalidate Sanas.ai’s real‑time accent‑correction patent. The petition alleges obviousness over multiple prior‑art references covering speech‑processing modules. All 18 claims are challenged.
Meta Platforms, Inc. v.COGMEDIA LLC
Meta Platforms has filed an IPR petition challenging all 28 claims of COGMEDIA’s ’141 Patent, asserting that the claimed social‑card UI features were obvious over earlier patents such as McQueen and Forsyth.
Meta Platforms, Inc. v.COGMEDIA LLC
Meta Platforms has filed a petition to invalidate Cogmedia’s ’562 patent covering social‑card interfaces, asserting that the claims are obvious over a suite of earlier patents. The petition challenges 14 claims and seeks institution of the IPR.
Krisp Technologies, Inc. v.Sanas.AI, Inc.
Krisp Technologies has filed an IPR petition challenging all 20 claims of Sanas.ai’s real‑time accent‑conversion patent, asserting obviousness over multiple prior‑art references. The petition invokes 35 U.S.C. § 103 and follows Phillips claim‑construction standards.
Microsoft Corporation v.Qomplx LLC
Microsoft has filed an IPR petition seeking to invalidate Qomplx’s 12,143,424 patent covering distributed stream‑processing graphs. The petition relies on Barsness and two later disclosures (Chakradhar and Siripurapu) to argue obviousness under §103 for nine claims.
Krisp Technologies, Inc. v.Sanas.AI, Inc.
Krisp Technologies has filed an IPR petition challenging all 20 claims of Sanas.AI’s real‑time accent‑correction patent, asserting obviousness over multiple prior‑art references. The petition details how each claim element is taught by combinations of Feinauer, Prabhavalkar, Fan and others.
Meta Platforms, Inc. v.COGMEDIA LLC
Meta Platforms has filed an IPR petition challenging all 29 claims of Cogmedia’s ’371 patent, asserting that the claimed card‑based social features were obvious over earlier systems such as McQueen and Forsyth. The petition seeks institution on the ground of obviousness under 35 U.S.C. §103.
Apriori Inc v.The Assistant Controller Of Patents And Designs
Apriori Inc filed an appeal before the Delhi High Court challenging the Assistant Controller's decision dated 15.12.2025, which refused to grant a patent for Indian Patent Application No. 202017008435. The court issued notice to the respondent and set a date for returnable hearing.
Viance, LLC v.Koppers Performance Chemicals, Inc.
Viance, LLC has filed a post‑grant review petition seeking cancellation of all 27 claims of Koppers' wood preservative patent (US 12,370,716), alleging lack of written description and that the claims are anticipated or obvious over multiple prior‑art references.
VideoAmp Inc. v.The Nielsen Company (US), LLC
VideoAmp has filed an IPR petition challenging all 30 claims of Nielsen’s audience‑measurement patent, asserting obviousness over Kerr and related prior art. The petition argues discretionary denial is unwarranted and seeks institution of the review.
Facing a similar IP matter?
Arctic Invent is a specialist IP firm with deep litigation expertise across India, EU, US, and UK. Our team uses data-driven strategy to build stronger cases.